Dupixent® by Sanofi received FDA marketing authorization in October 2018 for use as an add-on maintenance therapy in patients aged 12 years and older with moderate-to-severe asthma, particularly those with an eosinophilic phenotype or other specific conditions. In May 2019, the European Commission granted approval for Dupixent® to serve as an add-on maintenance treatment in patients aged 12 years and older who have severe asthma with type 2 inflammation and are inadequately controlled by high-dose inhaled corticosteroids, in conjunction with another maintenance medicinal product.

1. ASTHMA - DUPIXENT - SANOFI
By Pranay Kumar
:- pranayraju66@gmail.com

2. Introduction*
2
Asthma -Dupixent - Sanofi
Sanofi net sales of Dupixent by Region (Euro million)
Source: https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/2020_03_23_Sanofi-Report-2019-20F-
accessible.pdf?la=en&hash=14ACCB31D1FFFF966C8EA96CA7EE5049
❖ Dupixent - Sanofi
❖ Dupixent® was granted marketing authorization by the FDA in
October 2018 as an add-on maintenance therapy in patients with
moderateto-severe asthma aged 12 years and older with an
eosinophilic phenotype or with oral corticosteroid-dependent
asthma.
❖ In May 2019, the European Commission approved Dupixent® for
use as an add-on maintenance treatment in patients with severe
asthma aged 12 years and older with type 2 inflammation who are
inadequately controlled with high dose inhaled corticosteroid plus
another medicinal product for maintenance treatment.
2
216
1
75
660
53
200
1669
205
0
200
400
600
800
1000
1200
1400
1600
1800
Europe U.S Other Countries
2017 2018 2019
*Note: As per annual report description.

3. THANK YOU